Healthcare provider profile · identity verified

Joseph Kasper, MD

Internal Medicine · SADDLE RIVER, NJ · NPI 1437247558

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	514	166
Amlodipine Besylate	Amlodipine Besylate	375	119
Levothyroxine Sodium	Levothyroxine Sodium	315	89
Hydrochlorothiazide	Hydrochlorothiazide	209	58
Escitalopram Oxalate	Escitalopram Oxalate	190	49
Metoprolol Succinate	Metoprolol Succinate	185	67
Lisinopril	Lisinopril	160	49
Eliquis	Apixaban	158	57
Omeprazole	Omeprazole	126	47
Pantoprazole Sodium	Pantoprazole Sodium	123	41
Losartan Potassium	Losartan Potassium	119	50
Gabapentin	Gabapentin	112	44
Allopurinol	Allopurinol	100	22
Simvastatin	Simvastatin	97	31
Furosemide	Furosemide	92	42
Sertraline Hcl	Sertraline Hcl	90	28
Clopidogrel	Clopidogrel Bisulfate	88	22
Rosuvastatin Calcium	Rosuvastatin Calcium	86	26
Potassium Chloride	Potassium Chloride	79	29
Tamsulosin Hcl	Tamsulosin Hcl	75	34
Metformin Hcl	Metformin Hcl	72	28
Xarelto	Rivaroxaban	72	14
Metoprolol Tartrate	Metoprolol Tartrate	70	29
Prednisone	Prednisone	59	25
Alprazolam	Alprazolam	53	15
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	47	26
Donepezil Hcl	Donepezil Hcl	46	19
Mirtazapine	Mirtazapine	46	19
Torsemide	Torsemide	46	21
Duloxetine Hcl	Duloxetine Hcl	44	13
Quetiapine Fumarate	Quetiapine Fumarate	43	22
Glimepiride	Glimepiride	41	11
Esomeprazole Magnesium	Esomeprazole Magnesium	39	suppressed
Pregabalin	Pregabalin	39	suppressed
Famotidine	Famotidine	38	20
Memantine Hcl	Memantine Hcl	34	11
Alendronate Sodium	Alendronate Sodium	32	12
Montelukast Sodium	Montelukast Sodium	32	11
Synthroid	Levothyroxine Sodium	32	suppressed
Carvedilol	Carvedilol	31	16
Methylprednisolone	Methylprednisolone	31	27
Enoxaparin Sodium	Enoxaparin Sodium	28	13
Bupropion Xl	Bupropion Hcl	27	suppressed
Ozempic	Semaglutide	27	suppressed
Fluticasone Propionate	Fluticasone Propionate	26	12
Ramipril	Ramipril	26	suppressed
Mounjaro	Tirzepatide	24	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Diazepam	Diazepam	22	suppressed
Oxycodone Hcl	Oxycodone Hcl	22	17
Trazodone Hcl	Trazodone Hcl	22	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Tramadol Hcl	Tramadol Hcl	21	12
Amiodarone Hcl	Amiodarone Hcl	20	suppressed
Metformin Hcl Er	Metformin Hcl	20	suppressed
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Valsartan	Valsartan	20	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Divalproex Sodium	Divalproex Sodium	19	11
Finasteride	Finasteride	19	suppressed
Enalapril Maleate	Enalapril Maleate	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Atenolol	Atenolol	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Anastrozole	Anastrozole	14	suppressed
Colchicine	Colchicine	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	12
Farxiga	Dapagliflozin Propanediol	13	suppressed
Folic Acid	Folic Acid	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	11
Celecoxib	Celecoxib	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error